Corcept Therapeutics (CORT) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients. The firm expects to launch of Korlym within the next two to three months, with consensus sales forecasts for the drug running as high as $409M by 2016. Shares +68.1% premarket.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs